<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zheng Z</submitter><funding>Shanghai Frontier Research Base of Disease and Syndrome Biology of Inflammatory Cancer Transformation</funding><funding>the Shanghai Rising-Star Program</funding><funding>National Natural Science Foundation of China</funding><pagination>3810</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9736302</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(23)</volume><pubmed_abstract>The liver is the most common site for colorectal cancer (CRC)-associated metastasis. There remain unsatisfactory medications in liver metastasis given the incomplete understanding of pathogenic mechanisms. Herein, with an orthotopic implantation model fed either regular or high-fat diets (HFD), more liver metastases were associated with an expansion of conjugated bile acids (BAs), particularly taurocholic acid (TCA) in the liver, and an increased gene expression of Na&lt;sup>+&lt;/sup>-taurocholate cotransporting polypeptide (NTCP). Such hepatic BA change was more apparently shown in the HFD group. In the same model, TCA was proven to promote liver metastases and induce a tumor-favorable microenvironment in the liver, characterizing a high level of fibroblast activation and increased proportions of myeloid-derived immune cells. Hepatic stellate cells, a liver-residing source of fibroblasts, were dose-dependently activated by TCA, and their conditioned medium significantly enhanced the migration capability of CRC cells. Blocking hepatic BA uptake with NTCP neutralized antibody can effectively repress TCA-triggered liver metastases, with an evident suppression of tumor microenvironment niche formation. This study points to a new BA-driven mechanism of CRC-associated liver metastases, suggesting that a reduction of TCA overexposure by limiting liver uptake is a potential therapeutic option for CRC-associated liver metastasis.</pubmed_abstract><journal>Cells</journal><pubmed_title>A High Hepatic Uptake of Conjugated Bile Acids Promotes Colorectal Cancer-Associated Liver Metastasis.</pubmed_title><pmcid>PMC9736302</pmcid><funding_grant_id>82030118</funding_grant_id><funding_grant_id>2021KJ03-12</funding_grant_id><funding_grant_id>81830120</funding_grant_id><funding_grant_id>No. 22QA1408700</funding_grant_id><funding_grant_id>82204893</funding_grant_id><pubmed_authors>Zheng Z</pubmed_authors><pubmed_authors>He F</pubmed_authors><pubmed_authors>Yuan F</pubmed_authors><pubmed_authors>Zhao L</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Guo H</pubmed_authors><pubmed_authors>Ke Z</pubmed_authors><pubmed_authors>Jia F</pubmed_authors><pubmed_authors>Wei J</pubmed_authors><pubmed_authors>Hou X</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>A High Hepatic Uptake of Conjugated Bile Acids Promotes Colorectal Cancer-Associated Liver Metastasis.</name><description>The liver is the most common site for colorectal cancer (CRC)-associated metastasis. There remain unsatisfactory medications in liver metastasis given the incomplete understanding of pathogenic mechanisms. Herein, with an orthotopic implantation model fed either regular or high-fat diets (HFD), more liver metastases were associated with an expansion of conjugated bile acids (BAs), particularly taurocholic acid (TCA) in the liver, and an increased gene expression of Na&lt;sup>+&lt;/sup>-taurocholate cotransporting polypeptide (NTCP). Such hepatic BA change was more apparently shown in the HFD group. In the same model, TCA was proven to promote liver metastases and induce a tumor-favorable microenvironment in the liver, characterizing a high level of fibroblast activation and increased proportions of myeloid-derived immune cells. Hepatic stellate cells, a liver-residing source of fibroblasts, were dose-dependently activated by TCA, and their conditioned medium significantly enhanced the migration capability of CRC cells. Blocking hepatic BA uptake with NTCP neutralized antibody can effectively repress TCA-triggered liver metastases, with an evident suppression of tumor microenvironment niche formation. This study points to a new BA-driven mechanism of CRC-associated liver metastases, suggesting that a reduction of TCA overexposure by limiting liver uptake is a potential therapeutic option for CRC-associated liver metastasis.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2026-06-20T03:22:11.154Z</modification><creation>2025-04-20T03:32:07.283Z</creation></dates><accession>S-EPMC9736302</accession><cross_references><pubmed>36497071</pubmed><doi>10.3390/cells11233810</doi></cross_references></HashMap>